Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05656521Phase 2Unknown

101-PGC-005 for the Treatment of COVID-19

Role: lead

NCT05195749Phase 2Terminated

A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

Role: lead

NCT05619770Phase 1Unknown

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Role: lead

All 3 trials loaded